Chronic Hand Eczema

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Among systemic-experienced patients, delgocitinib cream still achieved statistically significant efficacy advantages over cream vehicle across all measured outcomes.

Molecular NOS2/CCL27 testing outperforms standard biopsy reads for psoriasis versus eczema, reducing diagnostic uncertainty in CHE and speeding targeted treatment.

This review of the latest dermatological studies includes insights on chronic hand eczema patch testing, case reporting, microbiome impact, and more.

A prospective study found that patch testing identified relevant allergens in 43% of patients with hand and foot eczema, with potassium dichromate being the most common sensitizer.

NFBC1966 data from Finland show that hand eczema is associated with poorer self-rated work ability among middle-aged adults, particularly among those with certain risk factors.

At week 16, 73.3% of patients receiving delgocitinib achieved a clinically meaningful improvement (≥ 4 points) in Dermatology Life Quality Index score vs 47.8% with vehicle.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, highlighted that CHE is often mischaracterized and frequently involves overlapping subtypes.

In a recent Expert Perspectives video series, Omar Noor, MD, discussed the complexity of chronic hand eczema and how a topical pan-JAK inhibitor can improve quality of life.

Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.

A new US consensus clarifies chronic hand eczema (CHE) diagnosis and stepwise care, highlighting FDA-approved treatment and patient-reported outcomes.

The RWEAL study uncovers real-world management of chronic hand eczema (CHE), highlighting treatment gaps and the need for standardized assessment in clinical practice.

CHE has gained attention in 2025 with an FDA-approved treatment and new insights, addressing its significant impact on patients' lives and work.

Comprehensive patch testing is vital for accurately diagnosing various forms of dermatitis, improving patient care, and addressing public health challenges.

Explore the emotional and physical challenges of chronic hand eczema through a patient's journey and expert insights on empathetic care and innovative treatments.

Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

High-dose topical delgocitinib significantly outperformed oral alitretinoin in reducing HECSI severity at both 12 and 16 weeks.

Clinical trials DELTA 1, 2, 3, and DELTA FORCE demonstrated significant improvements in CHE severity and patient-reported outcomes with delgocitinib.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

New research highlights the link between isotretinoin dosage and increased chronic hand eczema, emphasizing the need for careful monitoring during acne treatment.

Delgocitinib showed consistent efficacy in atopic, irritant, allergic, and hyperkeratotic forms of chronic hand eczema in pooled trial data.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

LEO Pharma's delgocitinib cream for chronic hand eczema is now available to prescribe in the US.